Table 2.

Events and risk in patients according to presence of WRF and treatmenta

EventsΔ Cr ≤ 0.3(n = 1631)Δ Cr > 0.3(n = 223)Unadjusted HR (95% CI)Adjusted HR (95% CI)bAdjusted HR by Treatmentc (95% CI; n = 1813)
Placebo(n = 916)Captopril(n = 897)d
Death316 (19.4%)58 (26.0%)1.46 (1.10 to 1.93)1.46 (1.05 to 2.02)1.63 (1.05 to 2.52)1.33 (0.81 to 2.21)
Cardiovascular death260 (15.9%)51 (22.9%)1.55 (1.15 to 2.09)1.62 (1.14 to 2.30)1.74 (1.07 to 2.81)1.56 (0.92 to 2.63)
MI205 (12.6%)32 (14.3%)1.23 (0.84 to 1.78)1.04 (0.66 to 1.66)1.38 (0.78 to 2.47)0.70 (0.31 to 1.54)
CHF236 (14.5%)39 (17.5%)1.48 (1.05 to 2.07)1.35 (0.91 to 2.01)1.53 (1.08 to 2.16)1.20 (0.82 to 1.75)
Composite end pointe564 (34.6%)94 (42.1%)1.41 (1.14 to 1.76)1.32 (1.03 to 1.70)1.53 (1.08 to 2.16)1.20 (0.82 to 1.75)
  • a CI, confidence interval; HR, hazard ratio.

  • b Adjusted for age, gender, baseline creatinine (<1.0, 1.0 to <2.0, and ≥2.0 mg/dl), history of hypertension, history of diabetes, history of dyslipidemia, history of CHF, left ventricular ejection fraction, previous MI, use of diuretics, and treatment assignment.

  • c From the original cohort of 1854 patients, 41 who were not taking captopril at 2 wk as a result of adverse drug reactions (e.g., hypotension, dizziness) were excluded for stratification of risk associated with WRF by treatment.

  • d Test for interaction: P > 0.15.

  • e Death, MI, CHF hospitalization, and stroke.